MX2012003398A - Agonistas npr-b novedosos. - Google Patents

Agonistas npr-b novedosos.

Info

Publication number
MX2012003398A
MX2012003398A MX2012003398A MX2012003398A MX2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A MX 2012003398 A MX2012003398 A MX 2012003398A
Authority
MX
Mexico
Prior art keywords
agonists
npr
new
new npr
unconventional
Prior art date
Application number
MX2012003398A
Other languages
English (en)
Spanish (es)
Inventor
Gerd Hummel
Frank Osterkamp
Heiko Hawlisch
Tobias Knaute
Ulf Reimer
Ulrich Reineke
Uwe Richter
Bernadett Simon
Markus Woischnik
Mark R Hellberg
Edgar Specker
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2012003398A publication Critical patent/MX2012003398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012003398A 2009-09-25 2010-09-23 Agonistas npr-b novedosos. MX2012003398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Publications (1)

Publication Number Publication Date
MX2012003398A true MX2012003398A (es) 2012-04-10

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR20180049198A (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX2012003398A (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2636738C2 (enExample)
TW (2) TWI577384B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732406B2 (en) 2005-04-07 2010-06-08 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
JP5345532B2 (ja) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
PH12012500562A1 (en) 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
CA2853204A1 (en) * 2011-12-16 2013-06-20 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
NZ710246A (en) * 2013-01-25 2016-11-25 Cardiorentis Ltd Methods of treating cardiovasular indications
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
CA3056433A1 (en) 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
US20210121534A1 (en) * 2018-06-19 2021-04-29 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
EP3880685B1 (en) * 2018-11-16 2025-06-18 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
US20230416328A1 (en) * 2020-06-12 2023-12-28 Hirofumi Tachibana C-Type Natriuretic Peptides and Methods Thereof in Treating Acute Lung Injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
EP0323740A3 (en) * 1987-12-24 1990-12-12 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006005140A2 (en) * 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007034498A1 (en) * 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
PH12012500562A1 (en) 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Also Published As

Publication number Publication date
EP2480247A2 (en) 2012-08-01
US20160194357A1 (en) 2016-07-07
KR101768661B1 (ko) 2017-08-16
TWI577384B (zh) 2017-04-11
UY32902A (es) 2011-02-28
EP2480247A4 (en) 2013-09-04
AU2010298256A1 (en) 2012-04-12
ZA201702958B (en) 2018-08-29
WO2011038061A2 (en) 2011-03-31
JP2017137362A (ja) 2017-08-10
KR20180049198A (ko) 2018-05-10
US20110077381A1 (en) 2011-03-31
US20170313743A1 (en) 2017-11-02
JP6211032B2 (ja) 2017-10-11
US20180334477A1 (en) 2018-11-22
RU2012116531A (ru) 2013-10-27
AU2010298256B2 (en) 2015-08-13
CA2773949A1 (en) 2011-03-31
RU2015124607A (ru) 2015-12-10
CA2773949C (en) 2020-11-03
KR101854820B1 (ko) 2018-05-04
KR20170094564A (ko) 2017-08-18
CL2017001190A1 (es) 2017-12-01
US9169293B2 (en) 2015-10-27
CL2012000715A1 (es) 2012-11-30
TWI625126B (zh) 2018-06-01
BR112012006579A2 (pt) 2016-11-22
CN102548574B (zh) 2016-03-23
RU2017139870A3 (enExample) 2019-05-16
MX354005B (es) 2018-02-08
ZA201201630B (en) 2014-05-28
RU2557290C2 (ru) 2015-07-20
US8546523B2 (en) 2013-10-01
US20130345394A1 (en) 2013-12-26
KR20120091110A (ko) 2012-08-17
EP2480247B1 (en) 2020-02-12
PH12012500562A1 (en) 2012-10-22
AR078445A1 (es) 2011-11-09
CN105732767A (zh) 2016-07-06
WO2011038061A3 (en) 2011-07-28
US9745344B2 (en) 2017-08-29
ZA201401625B (en) 2018-08-25
MX370645B (es) 2019-12-19
JP2013505937A (ja) 2013-02-21
US10196423B2 (en) 2019-02-05
JP5893561B2 (ja) 2016-03-23
JP2015131856A (ja) 2015-07-23
RU2017139870A (ru) 2019-05-16
RU2636738C2 (ru) 2017-11-28
CN102548574A (zh) 2012-07-04
US9982016B2 (en) 2018-05-29
TW201110974A (en) 2011-04-01
TW201630619A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
MX354005B (es) Agonistas npr-b novedosos.
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
CY1122794T1 (el) Συνθεσεις αλφα-γαλακτοσιδασης
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
UY31597A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
DOP2012000244A (es) Nuevos péptidos y métodos para su preparación y uso
AR087070A1 (es) Proteinas de fusion liberadoras de relaxina y usos de las mismas
PA8802301A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
CL2011002036A1 (es) Analogo peptidico doble agonista de los receptores de glp-1 y de glucagon.
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
IL216718A0 (en) Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
MX2010004297A (es) Antagonistas de glucagon.
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
BRPI0911984A2 (pt) sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
UA118167C2 (uk) Пептид та його застосування
PH12013500167A1 (en) Polypeptidic tyrosinase inhibitor
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
BR112018013071A2 (pt) uso de derivados de triptofano para formulações de proteínas
EP2819682A4 (en) TOPICAL GELS WITH ALPHA CONNEXIN C TERMINALS PEPTIDES (ACT)
WO2011146922A3 (en) Materials and methods for treatment of inflammation
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
CO6331291A2 (es) Peptidos de señalizacion de la crkl

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: SHIRE ORPHAN THERAPIES GMBH